Azitra, Inc. (AZTR)
$0.17+$0.01 (+4.74%) Latest session
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
No Form 4 activity for AZTR in the last 90 days.
10 Form 4 filings on record, the earliest from Dec 22, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Francisco D. Salva - Officer | Other | Common Stock | 4,064,050 | - | - | |
| Francisco D. Salva - Officer | Other | Series A Convertible Non-Redeemable Preferred Stock | 500 | - | - | |
| Norm Staskey - Officer | Grant or award | Stock Options (Right To Buy) | 35,524 | $0.00 | - | |
| Francisco D. Salva - Officer | Grant or award | Stock Options (Right To Buy) | 220,879 | $0.00 | - | |
| Travis Whitfill - Officer | Grant or award | Stock Options (Right To Buy) | 64,300 | $0.00 | - | |
| Francisco D. Salva - Officer | Open-market purchase | Series A Convertible Non-Redeemable Preferred Stock | 500 | - | - | |
| Francisco D. Salva - Officer | Open-market purchase | Series B Warrants | 4,064,050 | - | - | |
| Francisco D. Salva - Officer | Open-market purchase | Series C Warrants | 4,064,050 | - | - | |
| Travis Whitfill - Officer | Grant or award | Stock Options (Right To Buy) | 23,724 | $0.00 | - | |
| Francisco D. Salva - Officer | Grant or award | Stock Options (Right To Buy) | 59,309 | $0.00 | - | |
| Barbara Ryan - Director | Grant or award | Stock Options (Right To Buy) | 3,003 | $0.00 | - | |
| Norm Staskey - Officer | Grant or award | Stock Options (Right To Buy) | 15,015 | $0.00 | - | |
| John R. Schroer - Director | Grant or award | Stock Options (Right To Buy) | 3,003 | $0.00 | - |
Azitra, Inc. (AZTR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-18. The full record for AZTR runs to 10 Form 4 filings, the earliest from 2025-12-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AZTR were filed in the last 90 days. 3 purchases are on record for this company.
No insider sales of AZTR were filed in the last 90 days.
This page tracks AZTR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AZTR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
